Drug Patents owned by Hospira
1. List of Precedex drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8455527 | HOSPIRA | Methods of treatment using a dexmedetomidine premix formulation |
Jan, 2032
(8 years from now) | |
| US8648106 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(8 years from now) | |
| US9616049 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(8 years from now) | |
| US8242158 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(8 years from now) | |
| US10016396 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(8 years from now) | |
| US9320712 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(8 years from now) | |
| US8338470 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(8 years from now) | |
|
US8648106
(Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(9 years from now) | |
|
US8242158
(Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(9 years from now) | |
|
US8455527
(Pediatric) | HOSPIRA | Methods of treatment using a dexmedetomidine premix formulation |
Jul, 2032
(9 years from now) | |
|
US8338470
(Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(9 years from now) | |
|
US9320712
(Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(9 years from now) | |
|
US9616049
(Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(9 years from now) | |
Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient
Market Authorisation Date: 17 December, 1999
Treatment: Use for sedation
Dosage: INJECTABLE;INJECTION
How can I launch a generic of PRECEDEX before it's patent expiration?
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic